Treatment for Colorectal Cancer Varies by Hospital
the Cancer Therapy Advisor take:
There is a stable variation in hospital treatment patterns for patients with metastatic colorectal cancer (CRC), according to an article published online in Cancer.
The study evaluated treatment patterns of 84,161 patients who were recently diagnosed with metastatic CRC from 1,051 hospitals using data from 2006 through 2011 in the National Cancer Data Base.
The hospitals were evaluated on the use of different treatment procedures, such as primary site resection, metastatic site resection, chemotherapy, and palliative care.
Other evaluation factors included variation in the receipt of treatment according to the relative volume of services used by the hospitals and the variation of treatment patterns at the hospitals over the past decade.
Results showed that the overall use of volume of services varied greatly between hospitals with low volumes of service and hospitals with high volumes of service (5.0% compared to 22.3%, respectively).
A direct relationship between hospitals’ volumes of services and adjusted rates of metastatic site surgery and multiagent chemotherapy was found: as the volumes of services increased, the use of metastatic site surgery increase (6.6% to 30.8%; P<0.001) as did multiagent chemotherapy (37.8% to 57.4%; P<0.001). Similarly, the rate of palliative care also increased (8.1% to 11.3%; P=0.002).
However, the rate of use of primary site resection demonstrated little difference (56.8% vs. 59.5%; P=0.024).
The study found that hospital treatment patterns were stable over time and consistent with the data above.
There is a stable variation in hospital treatment patterns for patients with metastatic colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia